Zofran Heart Problems

Intravenous use of anti-nausea drug Zofran (generic: ondansetron) may affect the heart’s electrical activity and potentially pre-dispose patients to an abnormal and potentially fatal heart rhythm, according to research carried out by the drug’s manufacturer. The FDA announced that results of a clinical study found that the 32-milligram single IV dose of Zofran may extend the amount of time between two waves in the heart’s electrical cycle, known as the “QT interval,” putting patients at risk for a lethal and irregular heart rhythm called Torsade de Pointes. An episode of Torsade de Points can result in permanent brain damage, sudden death and ventricular fibrillation, a potentially fatal condition which causes the heart to beat so fast that it stops pumping blood effectively.

What is Torsade de Pointes and Why Is It Dangerous?

A person's QT interval is essentially the amount of time it takes for the heart's muscle to contract and recover. When this interval is prolonged, abnormal heart rhythms, including Torsade de Pointes may occur. Torsade de Pointes describes a rare but potentially deadly form of ventricular tachycardia (fast heart rhythm) which can cause fainting or death, as less blood is being supplied to the brain. It can occur without warning and is typically only diagnosed using an electrocardiogram. Left untreated, episodes of Torsade de Pointes can last for more than a minute, resulting in ventricular fibrillation, a heart rhythm problem which causes the ventricles to quiver uselessly instead of pumping blood to vital organs. Ventricular fibrillation can result in sudden death or coma, though those who survive may suffer from nerve problems and/or reduced mental perception.

Which Zofran Users are at Risk for Abnormal Heart Rhythms?

Zofran users who may be at risk for developing Torsade de Points include those taking drugs which prolong the QT intervals and those predisposed to low levels of magnesium and potassium in the blood. Patients with the following underlying conditions may also be at particular risk:

  • Congenital long QT syndrome
  • Congestive heart failure
  • Bradyarrhytmias (slow heartbeat)
  • Electrolyte abnormalities {: .circle}

According to the FDA, patients experiencing shortness of breath, fainting, dizziness or irregular heartbeats on Zofran should seek immediate medical care.

GSK Pulls 32mg Dose, Updates Label

In Sept. 2011, the FDA announced that abnormal heart rhythms may be associated with the use of Zofran and that it was requiring GlaxoSmithKline to conduct a thorough study to determine the degree to which the drug could prolong the QT interval. The preliminary results of this study were released in June 2011 and found that the 32mg single IV dose could predispose patients to Torsade{: target="_blank"} de Pointes as a result of its prolongation of the QT interval. GlaxoSmithKline announced that it would remove this dose from the label of the drug. The updated label will state that adults and children with nausea and vomiting from chemotherapy can continue to be treated intravenously with the drug at a recommended, lower dose.

We maintain a dedicated class action website. Our attorneys represent clients in many different class actions. Contact us for more information. We can help with any further medical complications you might experience.


" They really care, know what they are doing and treat you as though you are their only client! "

~ Robert

Insurance Offer$200,000
turned into
What we got $1,200,000
" Made this difficult legal matter as painless as possible and helped lead us to victory. "

~ Catherine

Insurance Offer$60,000
turned into
What we got $1,050,000
" Outstanding firm that has their clients interest at heart. "

~ Derrick

Insurance Offer$200,000
turned into
What we got $3,500,000
" They really set the bar high...I highly recommend. "

~ Carole

Insurance Offer$5,000
turned into
What we got $2,000,000
" They made everything hassle free, which is exactly what I needed in my busy life. "

~ Smith

Insurance Offer$5,000
turned into
What we got $367,000
" Helped me every step of the way! "

~ Pappadakis

Insurance Offer$100,000
turned into
What we got $2,602,150

Offices near You

Fort Lauderdale
5300 NW 33rd Ave, Suite 219
2451 Crittenden Drive, 40217
Panama City
1022 W. 23rd St., Suite 630 32405
101 Riverfront Blvd, Suite 600 34205
4495 South Semoran Boulevard, 32807
5801 West Colonial, 32808
500A Northside Crossing, Suite 9 31210
170 Meeting Street, Suite 110 29401
777 Gloucester Street, Suite 400 31520
402 South Kentucky Avenue, Suite 402 33801

Current call wait: 11 seconds

Client Testimonial Videos

Free Zofran Heart Problems Case Review

Share your experience and we will call you

or Call Now

By submitting you agree to our Terms & Privacy Policy.